United Therapeutics Corporation (UTHR)
UTHR Stock Price Chart
Explore United Therapeutics Corporation interactive price chart. Choose custom timeframes to analyze UTHR price movements and trends.
UTHR Company Profile
Discover essential business fundamentals and corporate details for United Therapeutics Corporation (UTHR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jun 1999
Employees
1.40k
Website
https://www.unither.comCEO
Martine A. Rothblatt
Description
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTHR Financial Timeline
Browse a chronological timeline of United Therapeutics Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is $7.07, while revenue estimate is $805.22m.
Earnings released on 6 May 2026
EPS came in at $5.82 falling short of the estimated $7.00 by -16.86%, while revenue for the quarter reached $781.50m , missing expectations by -1.99%.
Earnings released on 25 Feb 2026
EPS came in at $7.70 surpassing the estimated $7.13 by +7.99%, while revenue for the quarter reached $790.20m , missing expectations by -2.81%.
Earnings released on 29 Oct 2025
EPS came in at $7.16 surpassing the estimated $6.89 by +3.92%, while revenue for the quarter reached $799.50m , missing expectations by -1.88%.
Earnings released on 30 Jul 2025
EPS came in at $6.41 falling short of the estimated $7.29 by -12.07%, while revenue for the quarter reached $798.60m , missing expectations by -0.41%.
Earnings released on 30 Apr 2025
EPS came in at $6.63 surpassing the estimated $6.29 by +5.41%, while revenue for the quarter reached $794.40m , beating expectations by +2.02%.
Earnings released on 26 Feb 2025
EPS came in at $6.19 falling short of the estimated $6.40 by -3.28%, while revenue for the quarter reached $735.90m , beating expectations by +0.16%.
Earnings released on 30 Oct 2024
EPS came in at $6.39 falling short of the estimated $6.43 by -0.62%, while revenue for the quarter reached $748.90m , beating expectations by +3.64%.
Earnings released on 31 Jul 2024
EPS came in at $5.85 falling short of the estimated $6.40 by -8.59%, while revenue for the quarter reached $714.90m , beating expectations by +3.33%.
Earnings released on 1 May 2024
EPS came in at $6.17 surpassing the estimated $5.65 by +9.20%, while revenue for the quarter reached $677.70m , beating expectations by +8.61%.
Earnings released on 21 Feb 2024
EPS came in at $4.36 surpassing the estimated $4.19 by +4.06%, while revenue for the quarter reached $614.70m , beating expectations by +6.74%.
Earnings released on 1 Nov 2023
EPS came in at $5.38 surpassing the estimated $5.04 by +6.75%, while revenue for the quarter reached $609.40m , beating expectations by +3.66%.
Earnings released on 2 Aug 2023
EPS came in at $5.24 surpassing the estimated $4.51 by +16.19%, while revenue for the quarter reached $596.50m , beating expectations by +13.80%.
Earnings released on 3 May 2023
EPS came in at $4.86 surpassing the estimated $4.52 by +7.52%, while revenue for the quarter reached $506.90m , missing expectations by -1.45%.
Earnings released on 22 Feb 2023
EPS came in at $2.67 falling short of the estimated $4.51 by -40.80%, while revenue for the quarter reached $491.50m , missing expectations by -5.34%.
Earnings released on 2 Nov 2022
EPS came in at $4.91 surpassing the estimated $3.89 by +26.22%, while revenue for the quarter reached $516.00m , beating expectations by +4.62%.
Earnings released on 3 Aug 2022
EPS came in at $2.41 falling short of the estimated $4.13 by -41.65%, while revenue for the quarter reached $466.90m , beating expectations by +1.27%.
Earnings released on 4 May 2022
EPS came in at $5.03 surpassing the estimated $3.35 by +50.15%, while revenue for the quarter reached $461.90m , beating expectations by +9.96%.
Earnings released on 24 Feb 2022
EPS came in at $2.35 falling short of the estimated $3.72 by -36.83%, while revenue for the quarter reached $415.20m , missing expectations by -2.90%.
Earnings released on 3 Nov 2021
EPS came in at $3.42 falling short of the estimated $3.59 by -4.74%, while revenue for the quarter reached $444.70m , beating expectations by +1.51%.
Earnings released on 4 Aug 2021
EPS came in at $3.65 surpassing the estimated $3.02 by +20.86%, while revenue for the quarter reached $446.50m , meeting expectations.
UTHR Stock Performance
Access detailed UTHR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
